Coherus Will Launch US Lucentis Biosimilar By 2021
Deal With Bioeq Pulls Forward Ranibizumab Launch By Two Years
Buoyed by the success of its Udenyca pegfilgrastim biosimilar, Coherus has struck a deal with Bioeq to acquire commercialization rights to its biosimilar version of Lucentis (ranibizumab) in the US, eyeing a launch date of 2021.
